Discovered in 1994, KSHV is a human oncogenic gammaherpesvirus [1]. KSHV is causatively associated with several malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and KSHV inflammatory cytokine syndrome (KICS), most of which are commonly found in HIV-1infected individuals [1,2,3,4]. KS is a multifocal mesenchymal neoplasm characterized by neo-angiogenesis, inflammatory infiltration, and spindle-shaped tumor cells that express mixed cellular markers, including vascular and lymphatic endothelial, mesenchymal, and hematopoietic precursor cells [5]. Early stage of KS primarily affects mucocutaneous tissues but advanced stage of KS is often involved with visceral organs [5]. KS is one of the most common malignancies in AIDS patients. While the advent of antiretroviral therapy has substantially reduced the incidence of KS in Western countries, it has stabilized or even rebound in recent years in some populations, and continues to be the most common cancer in some African regions [6]. Hence, KS remains to be one of the most important malignancies in AIDS patients causing significant morbidity and mortality.PEL is a rare and aggressive non-Hodgkin's B cell lymphoma clinically characterized by lymphomatous effusions in body cavities usually without tumor masses [7]. PEL often occurs in advanced AIDS patients with a decreased CD4 T cell count at diagnosis. Approximately, half of PEL patients have KS or are at risk for developing KS. PEL is resistant to conventional chemotherapy with a short median survival of less than 6 months [7].MCD is a polyclonal B cell lymphoproliferative disorder characterized by inflammatory symptoms, including fever, cachexia, lymphadenopathy, splenomegaly, cytopenia, and hypoalbuminemia [8]. MCD in the setting of HIV is typically associated with KSHV infection and is usually fatal without treatment. Furthermore, there is no established standard of treatment for KSHV-associated MCD [8].